Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia

ISSN： 1386-341X

Source： Pituitary, Vol.14, Iss.1, 2011-03, pp. : 44-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Introduction to the special issue of pituitary: “Utility of growth hormone and IGF-I assays”

By Freda Pamela

Pituitary, Vol. 10, Iss. 2, 2007-06 ,pp. : 113-113

Springer Publishing Company

Access to resources Recommend Favorite

IGF-I measurements in the diagnosis of adult growth hormone deficiency

By Kwan Anita Hartman Mark

Pituitary, Vol. 10, Iss. 2, 2007-06 ,pp. : 151-157

Springer Publishing Company

Access to resources Recommend Favorite

Transforming Growth Factor-β Regulation of Estradiol-Induced Prolactinomas

By Hentges S. Sarkar D.K.

Frontiers in Neuroendocrinology, Vol. 22, Iss. 4, 2001-10 ,pp. : 340-363

Academic Press

Access to resources Recommend Favorite

IGF-I and postnatal growth of weaver mutant mice

By Yao Weiguo Zhong Jin Rosen Clifford Hock Janet Lee Wei-Hua

Endocrine Journal, Vol. 26, Iss. 2, 2005-03 ,pp. : 117-125

Humana Press, Inc

Access to resources Recommend Favorite

Sex-steroid modulation of growth hormone (GH) secretory control: Three-peptide ensemble regulation under dual feedback restraint by GH and IGF-I

By Veldhuis Johannes Bowers Cyril

Endocrine Journal, Vol. 22, Iss. 1, 2003-10 ,pp. : 25-39

Humana Press, Inc

Access to resources Recommend Favorite